** Brokerage Stifel starts coverage on drug developer Palvella Therapeutics PVLA.O with "buy" rating and $45 PT
** New PT represents a 65% upside to the stock's last close
** Stifel thinks PVLA has the potential to build a portfolio of rare skin disease treatments, "which collectively could have multi-billion-dollar potential"
** Stifel notes co's gel QTORIN optimizes for delivery of the treatment into the deepest regions of the skin with potency and high patient tolerability
** Including session's moves, PVLA stock more than doubled YTD
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。